Research Keyword: Cystic fibrosis

Penicillium and Talaromyces diversity in cystic fibrosis patient sample and the description of a new species, Penicillium subluteum sp. nov.

mycolabadmin

Researchers studied fungal infections in Dutch cystic fibrosis patients and discovered a surprising variety of Penicillium and Talaromyces species living in their lungs. They identified 75 different fungal species total, including a previously unknown species named Penicillium subluteum. The study emphasizes that these fungi should no longer be dismissed as harmless contaminants, as they may play important roles in lung disease and need to be accurately identified for proper patient management.

Read More »

Lack of correlation between in vitro and within patient measures of P. aeruginosa biofilms in cystic fibrosis

mycolabadmin

Researchers compared how Pseudomonas aeruginosa bacteria form biofilms (protective clusters) in lung samples from cystic fibrosis patients versus in laboratory culture dishes. They found that the bacteria behave quite differently in the lab compared to in patients’ lungs, suggesting that laboratory tests may not accurately predict how well antibiotics will work in real patients. This highlights the importance of studying bacteria directly from patient samples to better understand how infections actually develop and progress.

Read More »

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth

mycolabadmin

Researchers studied how Trikafta, a new cystic fibrosis medication, affects Aspergillus fungus growth. While Trikafta doesn’t directly kill the fungus, it makes antifungal drugs more effective and improves patients’ lung function to help clear infections naturally. However, high concentrations of the drug may reduce the immune system’s ability to fight the fungus, suggesting careful monitoring of patients is needed.

Read More »

Aspergillus in Children and Young People with Cystic Fibrosis: A Narrative Review

mycolabadmin

Cystic fibrosis is a serious genetic disease affecting children that damages the lungs through chronic infections. Aspergillus, a common mold in the environment, colonizes the airways of CF patients and can cause additional lung damage. While new CFTR modulator medications have improved outcomes and reduced Aspergillus infections, more research is needed to better diagnose and treat fungal infections in children with CF.

Read More »

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth

mycolabadmin

This study examines how Trikafta, a new cystic fibrosis medication, affects a common fungal lung infection (Aspergillus fumigatus). The researchers found that Trikafta doesn’t directly kill the fungus but does make it more susceptible to antifungal drugs and improves lung clearance. Surprisingly, at high concentrations, the medication actually reduced the immune response against the fungus in immune cells, suggesting the need for careful monitoring of patients on this therapy.

Read More »
Scroll to Top